An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback